SCI & TECH● LOWOct 2 · Oct 2, 2026, 3:20 PM
Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s
CNBC · global
Eli Lilly and Novo are developing new amylin drugs that serve as another biological lever to pull in treating obesity and diabetes.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Sci & Tech
SCI & TECH32m agoSA analyst: AI buildout faces major credit and energy bottlenecksSeeking Alpha TechSCI & TECH34m agoAntarctica’s ‘doomsday’ glacier will keep melting even if oceans coolNew ScientistSCI & TECH1h agoUkraine deposits seed samples in Svalbard Global Seed VaultUkrinform [en]SCI & TECH1h agoLeap second no longer of this time, international measurement authority abolishes itNOS Buitenland